米国企業
LIGAND PHARMACEUTICALS INC

LIGAND PHARMACEUTICALS INCLGND

時価総額

$15.1億

PER

28.9倍

	2011年 12月31日	2012年 12月31日	2013年 12月31日	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Royalties	-	-	-	-	-	-	-	129	47	34	49	73	84
Captisol	-	-	-	-	-	-	-	29	31	110	164	104	28
Contract	-	-	-	-	-	-	-	-	-	43	64	19	19
Total revenues	30	31	49	65	72	109	141	251	120	186	277	196	131
Cost of Captisol	-	-	-	-	-	-	-	-	11	30	62	53	11
Cost, Amortization	-	-	-	-	-	-	-	16	17	23	47	34	34
Research and development	10	11	9	12	13	21	27	28	56	59	69	36	25
General and administrative	15	16	18	23	24	27	29	38	42	64	57	70	53
Total operating costs and expenses	32	31	34	45	45	65	73	88	126	178	198	193	121
Gain from sale of Vernalis R&D	-	-	-	-	-	-	-	-	-	17	-	-	-
Gain on sale of Pelican	-	-	-	-	-	-	-	-	-	17	-	-	2
Income from continuing operations	-1	1	15	20	27	44	68	164	807	26	79	3	12
Gain (Loss) on Investments	-	-	-	-	-	-	-	-	3	-17	-4	29	46
Interest income	0	-	-	-	-	-	-	-	28	8	1	2	8
Interest expense	3	-	-	-	-	-	-	48	36	27	20	2	1
Other income (expense), net	1	1	-0	2	2	3	5	-6	-6	-0	-9	4	-2
Gain on derivative instruments	-	-	-	-	-	-	-	-	-	-	-	-	0
Total other income (expense), net	-2	-4	-6	-8	8	-36	-11	10	-10	-36	-32	33	52
Other income (expense), net	1	1	-0	2	2	3	5	-6	-6	-0	-9	4	-2
Total other income (expense), net	-2	-4	-6	-8	8	-36	-11	10	-10	-36	-32	33	52
Income before income tax from continuing operations	-3	-4	9	11	35	8	57	173	797	-11	47	36	64
Income tax benefit (expense)	-13	-	0	0	-220	10	45	30	167	-8	-10	41	10
Net income (loss) from continuing operations	10	-3	9	12	257	-	-	-	-	-	-	-5	54
Net loss from discontinued operations	-	-	-	-	-	-	-	-	-	-	-	-28	-2
Net income (loss):	10	-1	11	12	257	-2	13	143	629	-3	57	-33	52
Income (Loss) from Continuing Operations, Per Basic Share	-	-	0.43	0.59	13	-0.11	0.6	6.77	-	-	-	-0.31	3.11
Basic net income (loss) from discontinued operations (USD per share)	-	-	0.13	-	-	0.04	-	-	-	-	-	-1.67	-0.1
Basic net income (loss) per share (in USD per share)	-	-	0.56	0.59	13	-0.08	0.6	6.77	33.13	-0.18	3.44	-1.98	3.02
Income (Loss) from Continuing Operations, Per Diluted Share	-	-	0.43	0.56	12.12	-0.11	0.53	5.96	-	-	-	-0.31	3.03
Diluted net income (loss) from discontinued operations (USD per share)	-	-	0.12	-	-	0.04	-	-	-	-	-	-1.67	-0.09
Diluted net income (loss) per share (in USD per share)	-	-	0.55	0.56	12.12	-0.08	0.53	5.96	31.85	-0.18	3.31	-1.98	2.94
Income (Loss) from Continuing Operations, Per Basic Share	-	-	0.43	0.59	13	-0.11	0.6	6.77	-	-	-	-0.31	3.11
Basic net loss from discontinued operations (in USD per share)	-	-	0.13	-	-	0.04	-	-	-	-	-	-1.67	-0.1
Basic net income (loss) per share (in USD per share)	-	-	0.56	0.59	13	-0.08	0.6	6.77	33.13	-0.18	3.44	-1.98	3.02
Income (Loss) from Continuing Operations, Per Diluted Share	-	-	0.43	0.56	12.12	-0.11	0.53	5.96	-	-	-	-0.31	3.03
Diluted net loss from discontinued operations (in USD per share)	-	-	0.12	-	-	0.04	-	-	-	-	-	-1.67	-0.09
Diluted net income (loss) per share (in USD per share)	-	-	0.55	0.56	12.12	-0.08	0.53	5.96	31.85	-0.18	3.31	-1.98	2.94